Takeda Pharmaceutical’s NEDD8-activating enzyme inhibitor pevonedistat cleared a key health ministry panel on July 30 for sakigake fast-track designation, opening the way for it to be the first drug to gain the status since the scheme earned full legal backing…
To read the full story
Related Article
- Takeda’s Pevonedistat Gets 1st Sakigake Tag under PMD Law
August 26, 2021
REGULATORY
- Cabinet-Backed Health Insurance Bill Targets Childbirth Costs, Copay Reform
March 16, 2026
- Japan Cabinet Approves Health Insurance Bill with OTC-Like Drug Charges
March 16, 2026
- LDP Urges Action on Drug Supply Risks Linked to Reliance on Specific Countries
March 16, 2026
- 874 Defects or Health Damages Reported for Regenerative Medical Products in 1H FY2025
March 13, 2026
- Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
March 12, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





